Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial ECOGHNE1305-M


A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

Principal Investigator(s)

John Murray


  • Protocol No. ECOGHNE1305-M
  • Open Date: 02/11/2009
  • Staging: Phase III
  • Age Group: Adults
  • Scope: National
  • Objective: To compare the overall survival of patients with recurrent or metastatic head and neck cancer treated with standard cisplatin-based chemotherapy with or without bevacizumab.
  • Disease Sites: Head/Neck
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: None Specified
  • Participating Institutions: Baptist Hospital; Meharry Medical College
  • Secondary Protocol No: E1305


None Provided.


Not provided. Please call for more information.